HC Wainwright & Co. Reiterates Buy on Spruce Biosciences, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Spruce Biosciences (NASDAQ:SPRB) and maintained a $10 price target on the stock.
November 20, 2023 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Spruce Biosciences and maintained a $10 price target.
The reiteration of a Buy rating and the maintenance of a $10 price target by a reputable analyst could lead to increased investor confidence and a potential positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100